VEVYE
Growthcyclosporine ophthalmic solution
NDAOPHTHALMICSOLUTION
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Loss of Exclusivity
LOE Date
Apr 1, 2042
195 months away
Patent Expiry
Apr 1, 2042
Exclusivity Expiry
May 30, 2026